Vosoritide

• Description :

  Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3) . Vosoritide can be used in achondroplasia and dwarfism research[1][2][3].

• Product Name Alternative :

  BMN 111

• UNSPSC :

  12352209

• Target :

  FGFR

• Type :

  Peptides

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/vosoritide.html

• Purity :

  99.89

• Solubility :

  H2O : 50 mg/mL

• Smiles :

  O=C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CNC=N1)C(N2[C@@H](CCC2)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CSSC[C@@H](C(O)=O)NC4=O)C(N[C@@H](CC5=CC=CC=C5)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NC4)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]6NCCC6

• Molecular Formula :

  C176H290N56O51S3

• Molecular Weight :

  4102.73

• References & Citations :

  [1]Duggan S. Vosoritide: First Approval. Drugs. 2021 Nov;81 (17) :2057-2062.|[2]Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. JCI Insight. 2021 May 10;6 (9) :e141426.|[3]Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012 Dec 7;91 (6) :1108-14.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Scientific Category :

  Peptides

• Clinical Information :

  Launched

• CAS Number :

  [1480724-61-5]